Crystallization equipment for pharmaceutical APIs

01Overview and value chain

Markers: [EC: ICH Q8/Q9/Q10 & ICH Q13 continuous manufacturing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Crystallization equipment for pharmaceutical APIs is the set of vessels, coolers and continuous contactors that drive a purified active pharmaceutical ingredient out of solution into a solid crystal of defined polymorph, particle-size distribution and purity. It is the unit operation on which bioavailability, filterability and downstream drying all depend, and it is where the molecule becomes a processable solid. Three geometries dominate the field: batch draft-tube-baffled (DTB) and Oslo crystallizers for mid-volume APIs, plug-flow and MSMPR continuous crystallizers for high-volume steady-state production, and fractional-melt crystallizers for ultra-high-purity (electronic- or pharma-grade) isolation without solvent handling. The platform is mid-transformation along four axes: inline FBRM and PVM probes that close the loop on chord-length and crystal-shape in real time under ICH Q8 Quality-by-Design; the shift from batch to ICH Q13 continuous crystallization for high-volume APIs; automated parallel screening (Crystal16, Crystalline) that maps polymorph/solvent space in a single overnight run; and fractional-melt crystallization as a green, low-solvent purification route for high-value intermediates.

The key directions of pharmaceutical crystallization equipment are:

1. Automated parallel crystallization screening (Crystal16, Crystalline): Technobis platforms that run 16 or 96 parallel small-volume crystallizations under software control, sweeping solvent, cooling rate and anti-solvent composition to map the polymorph/solvent landscape before scale-up.
2. Industrial forced-circulation and draft-tube-baffled crystallizers (GEA Messo): the mid-volume workhorse geometry — forced-circulation (FC), draft-tube-baffled (DTB) and Oslo growth-type crystallizers for steroid, vitamin and antibiotic APIs.
3. Continuous and melt crystallization (Sulzer Chemtech): plug-flow and MSMPR continuous crystallizers for steady-state ICH Q13 production, and fractional-melt crystallizers that exploit small impurity partition coefficients for electronic- and pharma-grade purity without solvent handling.
4. Inline PAT and closed-loop control (Mettler-Toledo FBRM/PVM, ReactIR): inline laser and video probes that track crystal chord-length, shape and supersaturation in real time, enabling Quality-by-Design closed-loop cooling under ICH Q8/Q9/Q10.

Sectoral value chain

[API solution preparation] ──> [crystallizer (DTB / continuous / melt)] ──> [crystal suspension]
                                                │
                                  (inline FBRM/PVM + supersaturation control)
                                                │
                                                ▼
[dried API] <─── [drying] <─── [solid-liquid separation] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Inline FBRM/PVM PAT (FBRM/PVM PAT): focused-beam reflectance and particle-video microscopy probes for real-time chord-length and crystal-shape tracking.
• Continuous crystallization (Continuous Crystallization): plug-flow and MSMPR geometries running at steady state under ICH Q13.
• Melt crystallization (Melt Crystallization): fractional freezing for ultra-high-purity isolation without solvent handling.

02US

The United States is the largest demand market for pharmaceutical crystallization equipment — most of the world’s top-20 API manufacturers run US-based process-development and validation groups — and FDA’s ICH Q8 Quality-by-Design and ICH Q13 continuous-manufacturing guidances are the regulatory drivers behind real-time FBRM/PVM closed-loop cooling and the batch-to-continuous transition. The crystallizer OEM base is European, so the US regional block describes the demand-and-adoption side rather than an indigenous OEM.

ICH Q8 QbD adoption, continuous-manufacturing validation, process-development demand

• FDA ICH Q8/Q9/Q10 Quality-by-Design: the framework that requires a defined polymorph control strategy and real-time release, pulling FBRM/PVM PAT into every new API filing.
• ICH Q13 continuous-manufacturing adoption: US filers lead on continuous crystallization submissions for high-volume APIs, validating plug-flow and MSMPR geometries.
• US process-development demand: the top-20 API manufacturers’ US process-development groups are the primary buyers of Technobis parallel-screening and Mettler-Toledo automated-lab-reactor platforms.

03CN

China is the fastest-growing production geography for pharmaceutical crystallization equipment: domestic API manufacturers supplying steroids, vitamins (ascorbic acid, B-group, D3) and antibiotics are scaling mid-volume DTB and Oslo crystallizer capacity, and NMPA’s adoption of ICH Q8/Q9/Q10/Q13 harmonises the Quality-by-Design and continuous- manufacturing framework with FDA and EMA. The crystallizer OEM base remains predominantly imported (European), so the CN regional block is held qualitative.

API scale-out, NMPA ICH Q8/Q13 alignment, imported OEM base

• Domestic API production scale-out: steroid, vitamin and antibiotic manufacturers run mid-volume DTB and Oslo crystallizer trains built around European (GEA, Sulzer) and PAT (Mettler-Toledo) hardware.
• NMPA ICH Q8/Q9/Q10/Q13 alignment: harmonised Quality-by-Design and continuous-manufacturing guidance, framing the regulatory route for FBRM/PVM closed-loop and continuous crystallization.
• Imported OEM base: the crystallizer and PAT OEM layer is predominantly European; domestic firms localise media, solvent recovery and downstream drying rather than the crystallizer itself.

04EU

Europe is the centre of pharmaceutical crystallization equipment manufacturing — all four crystallizer OEM classes and the dominant PAT platform are European. Technobis (Alkmaar, NL) builds the automated parallel-screening platforms; Sulzer Chemtech (Winterthur, CH) builds continuous and fractional-melt crystallizers; GEA Messo builds the industrial DTB, Oslo and forced-circulation workhorses; Syrris (Royston, UK, an Agilent company) supplies flow-chemistry and continuous-crystallization platforms; and Mettler-Toledo supplies the FBRM/PVM/ReactIR PAT suite. EMA’s ICH Q8/Q13 implementation completes the framework.

crystallizer OEMs, PAT platforms, EMA ICH Q8/Q13

• Technobis — Crystal16 & Crystalline: automated parallel crystallization screening platforms mapping polymorph and solvent space across 16–96 small-volume vessels.
• Sulzer Chemtech — SuPro & melt crystallizers: plug-flow continuous crystallizers and fractional-melt units for electronic- and pharma-grade purification.
• GEA Messo — DTB, Oslo, FC crystallizers: the industrial forced-circulation, draft-tube-baffled and Oslo growth-type workhorses for steroid, vitamin and antibiotic APIs.
• Syrris — Asia flow-chemistry/crystallization (Agilent): continuous-flow and batch-crystallization platforms for hazardous-reaction scale-up.
• Mettler-Toledo — FBRM, PVM, ReactIR: the inline PAT suite (focused-beam reflectance, particle video microscopy, mid-IR) that closes the crystallization control loop under ICH Q8.

05Leading companies and research institutes

06Tech stack and innovations

The stack combines the crystallizer vessel, the inline PAT probes and the Quality-by-Design control strategy into one closed, validated process.

1. Crystallizer geometries (Crystallizer Geometries):
   • batch draft-tube-baffled (DTB) and Oslo growth-type crystallizers (GEA Messo) for mid-volume APIs;
   • plug-flow and MSMPR continuous crystallizers (Sulzer SuPro) for steady-state ICH Q13 production;
   • fractional-melt crystallizers for ultra-high-purity, low-solvent isolation.
2. Inline PAT probes (Inline PAT Probes):
   • FBRM (focused-beam reflectance) tracking crystal chord-length distribution in real time;
   • PVM (particle video microscopy) imaging crystal shape and habit;
   • ReactIR mid-IR tracking solution concentration and supersaturation for feedback cooling.
3. Parallel screening & QbD control (Parallel Screening & QbD Control):
   • Technobis Crystal16 / Crystalline parallel platforms sweeping solvent and cooling-rate space overnight;
   • Quality-by-Design cooling profiles under ICH Q8 that hold the process inside the design space for polymorph control.

07Value chains and production pipelines

Industrial pipeline of a pharma-API crystallization train (ICH Q8/Q13)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. API solution prep      │ ───> │ 2. Crystallization        │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Solid-liquid separation│ <─── │ 3. PAT closed-loop control│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Drying                 │ ───> │ 6. Polymorph & release QC │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: API solution preparation

The purified API is dissolved in solvent or anti-solvent at a set concentration and temperature to give a clear, undersaturated starting solution.

Stage 2: Crystallization

Supersaturation is generated — by cooling, anti-solvent addition, evaporation or melt — in the crystallizer (DTB, Oslo, FC, plug-flow or melt), nucleating and growing crystals to a target polymorph and size.

Stage 3: PAT closed-loop control

Inline FBRM tracks crystal chord-length, PVM images crystal habit and ReactIR tracks supersaturation, feeding a Quality-by-Design cooling profile under ICH Q8 that holds the process inside the design space.

Stage 4: Solid-liquid separation

The crystal slurry is filtered or decanted from the mother liquor on a filter dryer or pusher centrifuge, yielding a wet crystal cake.

Stage 5: Drying

The wet cake is dried under vacuum or in a conical dryer to the target residual-solvent specification set by ICH Q3D.

Stage 6: Polymorph and release QC

X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and laser particle-size analysis confirm the polymorph, habit and size distribution before batch release against the regulatory specification.